摘要
目的:探讨诺维本联合顺铂(NP)及紫杉醇联合顺铂(TP)化疗方案辅助治疗老年ⅢA期非小细胞肺癌(NSCLC)的疗效及不良反应。方法:对2009年1月至2012年10月于我院肿瘤科住院治疗的43例老年(≥65岁)ⅢA期NSCLC患者进行化疗,分别使用诺维本联合顺铂(NP组,n=23)和紫杉醇联合顺铂(TP组,n=20)治疗,比较两组的疗效及不良反应。结果:NP组6例完全缓解,9例部分缓解,总有效率65.2%,疾病控制率82.6%;TP组6例完全缓解,7例部分缓解,总有效率65.0%,疾病控制率80.0%,两组疗效无显著差异;TP组死亡2例显著高于NP组死亡1例,(P<0.05);NP组肝功能损害Ⅰ度+Ⅱ度12例,Ⅲ度+Ⅳ度1例,TP组肝功能损害Ⅰ度+Ⅱ度11例,Ⅲ度+Ⅳ度6例,差异明显(P=0.03),其余不良反应,如白细胞减少、血小板减少、贫血、恶心呕吐、肾功能损害及脱发等均无明显差异(P>0.05)。结论:NP化疗方案辅助治疗老年ⅢA期NSCLC疗效好,不良反应少,值得推广。
Objective：To compare the therapeutic responses and toxicity of navelbine plus cisplatin （NP） and paclitaxel plus cisplatin （TP） in elderly patients （≥65 years） with stage ШA non-small cell lung cancer （NSCLC）. Methods：Chemotherapies were performed in the 43 elderly patients with stage ШA NSCLC in our hospital from Jan 2009 to Oct 2012. 23 patients received NP, and 20 patients received TP. The clinical effect and side actions were compared between the two groups. Results： There were 6 complete remission, 9 partial remission in NP group. There were 6 complete remission, 7 partial remission in TP group. The total response rates were 65.2% and 65.0% and the disease control rates were 82.6% and 80.0%, respectively. No significant differences existed in therapeutic effects. However, the fact that 2 patients in TP group died and 1 patient died in NP group ,the mortality were significant different between the two groups（P〈0.05）. Meanwhile, hepatic injury occurred in NP group, with 12 inⅠ＋Ⅱ and 1 in Ⅲ＋Ⅳ, and in TP group, with 11 in Ⅰ＋Ⅱ and 6 in Ⅲ＋Ⅳ. The significance between the two groups （P=0.03） indicated that NP caused less hepatic injury than TP. As to other adverse effects, like leukocytes decrease, platelets decrease, anemia, nausea and vomiting, kidney injury and hair loss, there were no significant differences （P〉0.05）. Conclusions：NP is an effective and tolerable regime for elderly patients with stage ШA NSCLC. It merits further application in clinical treatment.
出处
《岭南急诊医学杂志》
2015年第4期325-326,329,共3页
Lingnan Journal of Emergency Medicine
关键词
诺维本
顺铂
ⅢA期
非小细胞肺癌
老年
navelbine
cisplatin
Stage ШA
non-small cell lung cancer
elderly
